-

Shareholder Alert: Robbins LLP Reminds Investors Hamilton Beach Brands Holding Company (HBB) Sued for Misleading Shareholders

SAN DIEGO & GLEN ALLEN, Va.--(BUSINESS WIRE)--Shareholder rights law firm Robbins LLP reminds investors that a purchaser of Hamilton Beach Brands Holding Company (NYSE: HBB) filed a class action complaint against the Company for alleged violations of the Securities Exchange Act of 1934 between February 27, 2020 and May 8, 2020. Hamilton designs, markets, and distributes small electric household and specialty housewares appliances.

If you suffered a loss as a result of Hamilton's misconduct, click here.

Hamilton Beach Brands Holding Company (HBB) Accused of Misleading Shareholders

According to the complaint, on February 27, 2020, Hamilton filed its annual report for 2019 and assured investors that its "disclosure controls and procedures [were] effective" as well as its internal control over financial reporting. Later that day in an earnings call, Hamilton stated that its international markets, which includes Mexico, "have generated a compound annual growth rate of more than 5% in the past five years" and went on to state that "Mexico… [has] just taken off in the past year to 18 months and the team has done a great job to be really on the forefront of that market." Contrary to these positive presentations, on May 11, 2020, Hamilton revealed that it was unable to timely file its 1Q20 10-Q because of "certain accounting irregularities with respect to the timing of selling and marketing expenses and the classification of certain expenditures within the statement of operations at its Mexican subsidiary." On this news, Hamilton's stock price fell almost 9% to close at $10.43 per share.

Hamilton Beach Brands Holding Company (HBB) Shareholders Have Legal Options

Contact us to learn more:
Leo Kandinov
(800) 350-6003
lkandinov@robbinsllp.com
Shareholder Information Form

Want to be notified if a class action against Hamilton settles? Want to receive free alerts about companies engaged in wrongdoing? Sign up for Stock Watch today.

Attorney Advertising. Past results do not guarantee a similar outcome.

Contacts

Leo Kandinov
Robbins LLP
lkandinov@robbinsllp.com
(619) 525-3990 or Toll Free (800) 350-6003
www.robbinsllp.com

More News From Robbins LLP

Stockholder Alert: Robbins LLP Informs Investors of the Flotek Industries, Inc. (FTK) Class Action

SAN DIEGO--(BUSINESS WIRE)--Shareholder rights law firm Robbins LLP informs investors that a class action was filed on behalf of all persons and entities who purchased or otherwise acquired Flotek Industries, Inc. (NYSE: FTK) securities between August 3, 2026 and August 17, 2026 (the "Class Period"). Flotek is an energy technology and services company.The complaint alleges that Flotek misled investors by failing to disclose the cancellation of its $400m Puerto Rican deal.Investors who suffered s...

Robbins LLP Encourages WSE Stockholders with Large Losses to Seek Counsel for the Securities Class Action Lawsuit Against Wise Group plc

SAN DIEGO--(BUSINESS WIRE)--Robbins LLP reminds investors that a securities class action has been filed on behalf of all persons and entities that purchased or otherwise acquired Wise Group plc (NASDAQ: WSE) securities between May 11, 2026 and July 23, 2026 (the "Class Period").The complaint alleges that Wise and certain of its senior executives violated the federal securities laws by making materially false and/or misleading statements regarding the Company's anti-money laundering compliance, a...

Robbins LLP Urges Investors of ARS Pharmaceuticals Inc. to Contact the Firm for Information About the SPRY Securities Class Action Lawsuit

SAN DIEGO--(BUSINESS WIRE)--Robbins LLP reminds shareholders that a securities class action has been filed on behalf of all investors who purchased or otherwise acquired ARS Pharmaceuticals Inc. (NASDAQ: SPRY) securities between March 9, 2026 and June 24, 2026 (the "Class Period"). ARS is a clinical stage biopharmaceutical company focused on the development and commercialization of neffy for needle-free intranasal delivery of epinephrine for emergency treatment of Type 1 allergic reactions, incl...
Back to Newsroom